(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 1,160.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.32%.
Nrx Pharmaceuticals's revenue in 2025 is $242,000.On average, 6 Wall Street analysts forecast NRXP's revenue for 2025 to be $747,312,585, with the lowest NRXP revenue forecast at $481,874,303, and the highest NRXP revenue forecast at $1,032,587,792. On average, 6 Wall Street analysts forecast NRXP's revenue for 2026 to be $3,699,895,523, with the lowest NRXP revenue forecast at $1,173,019,732, and the highest NRXP revenue forecast at $7,121,905,516.
In 2027, NRXP is forecast to generate $15,284,828,112 in revenue, with the lowest revenue forecast at $14,101,075,086 and the highest revenue forecast at $16,360,405,273.